key: cord-0956587-o5vtewiz authors: Olguín-Manríquez, Francisco; Cernichiaro-Espinosa, Linda; Olguín-Manríquez, Arturo; Manríquez-Arias, Rebeca; Flores-Villalobos, Erick Omar; Kawakami-Campos, Perla Ayumi title: Unilateral acute posterior multifocal placoid pigment epitheliopathy in a convalescent COVID-19 patient date: 2021-05-25 journal: Int J Retina Vitreous DOI: 10.1186/s40942-021-00312-w sha: de5c296e3d29b68104591c35f719928772ab5916 doc_id: 956587 cord_uid: o5vtewiz BACKGROUND: To report a case of unilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) in a Hispanic convalescent COVID-19 female patient. Case presentation A 35-year-old Hispanic female with exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated due to unilateral visual loss. Ophthalmic examination and diagnostic tests were consistent with APMPPE. DISCUSSION: Ocular changes can be observed in patients with COVID-19. A complete ophthalmic evaluation must be performed in patients with low vision after SARS-CoV-2 infection. In February 2020, the International Committee on Taxonomy of Viruses (ICTV) announced the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a new virus. This name was chosen because the virus is genetically related to the coronavirus responsible for the SARS outbreak of 2003. The World Health Organization (WHO) named this new disease as "COVID-19" in February 2020. The disease quickly reached the size of a pandemic on March 11, 2020, due to the speed and scale of the transmission [1] . There are basically 3 stages or phases in the natural history of COVID-19, regarding disease severity. The first phase is related to the onset of the disease and is generally characterized by the development of influenza-like symptoms from mild to moderate. Some individuals recover and some progress to the second phase. During the second phase, it is possible to detect pneumonialike symptoms. Depending on the severity of phase two, patients can improve, or worsen with the necessity of intubation and ventilation. The phase three is characterized by hyper inflammation and sepsis of lungs. Patients often require intensive care unit and most of them unfortunately cannot overcome the infection and eventually die [2] . Ocular manifestations in COVID-19 patients may include conjunctivitis, chemosis, and epiphora. Higher neutrophil counts, procalcitonin, C-reactive proteins, and lactate dehydrogenase are factors associated with such signs [3] . Posterior segment manifestations may include retinal hemorrhages, cotton wool spots, and dilated retinal vessels. Higher veins diameter has been positively correlated with disease severity [4] . Interestingly, SARS-CoV-2 infects endothelial cells [5] . Hyper-reflective lesions at the level of inner plexiform and ganglion cell layers have been documented in twelve patients examined 11-33 days after the onset of COVID-19 symptoms [6] . Vitritis and disruption of the ellipsoid zone and hyperreflective lesions at the level of inner plexiform and ganglion cell layers have also been reported [7] . We present a case of a convalescent COVID-19 female patient with acute posterior multifocal placoid pigment epitheliopathy (APMPPE). A 35-year-old Hispanic female presented blurred vision, central scotoma and photopsia in her right eye. She had experienced fever, headaches and myalgia 6 weeks before initial consultation. The patient had past history of Diabetes mellitus diagnosed 3 years before, and good glucose control was obtained with insulin. She tested positive for SARS-Cov-2 IgG antibody 2 weeks before ophthalmic examination. Previous ocular history was unremarkable. A complete ophthalmological exam was performed. Best-corrected visual acuity (BCVA) was 20/400 in the right eye (RE) and 20/20 in the left eye (LE). Biomicroscopy of the anterior segment, pupillary reflexes, and intraocular pressure were normal in both eyes (OU). At fundus examination, multiple yellow-white placoid lesions were evident at the posterior pole in the RE (Fig. 1a) . LE posterior segment was unremarkable (Fig. 1b) . Fluorescein Angiography (FA) showed early hypofluorescence at the foveal lesions with late hyperfluorescence of all lesions ( Fig. 1c-d) . Fundus autofluorescence (FAF) revealed hypo-autofluorescence of all lesions surrounded by a hyper-autofluorescent halo (Fig. 1f ) . Optical Coherence Tomography (OCT) scans across the placoid lesions showed hyper-reflective material at the level of the outer retinal layers and disruption at the interdigitation zone in the foveal depression ( Fig. 1h-i) . Complete blood count with differential and tests for infectious disease (tuberculosis, syphilis, and toxoplasmosis) were requested-the results obtained were negative. Routine blood tests were normal. Based on imaging and clinical features, the patient was diagnosed with APMPPE. More commonly ocular manifestations have been reported in patients with COVID-19 such as conjunctivitis, chemosis, and epiphora in patients with severe systemic disease or abnormal findings on blood tests [3] . Our patient started with unilateral macular dysfunction 6 weeks after the onset of influenza-like symptoms. Laboratory tests found positive IgG antibody for SARS-CoV-2, showing serological evidence of past infection for COVID-19. Fundus photographs, FA, FAF, and OCT findings correlate well with previous descriptions of APMPPE lesions [14, 15] . APMPPE is an acute-onset inflammatory disease that affects the choriocapillaris, RPE, and outer retina. Numerous, yellow, creamy colored placoid lesions are seen in the posterior pole and are not seen anterior to the equator [13] . Up to one third of APMPPE cases worldwide have been described as related to a viral prodromic period. While viruses as type five Adenovirus and B4 Coxsackievirus have been typically associated with white dot syndromes, there have been reports of post vaccination disease. Its cause has not been clearly elucidated yet since the incidence of these syndromes is very low. However, Coxsackie antibody titers in acute and treated cases seem to correlate in some series [16] . Using multimodal imaging in APMPPE, some authors have found choroidal inflammation as a preceding and necessary factor for RPE, and subsequent damage in cones [16] . This choroidal inflammation may be generated solely by the entry of SARS-CoV-2 via the angiotensin-converting enzyme 2 receptor (ACE) in the endothelium. The presence and abundance of this receptor has already been found higher in COVID-19 fatal cases compared to controls [17] . In these patients the accumulation of mononuclear cells and neutrophils in the lumen and intima of choriocapillaris may prove the viral trigger for white dot syndromes. Detection of SARS-CoV-2 has been confirmed by Realtime reverse transcriptase-polymerase chain reaction (RT-PCR) in human retinal biopsies (RB) of deceased COVID-19 patients. Although ocular symptoms or changes in the posterior segment were not analyzed in these patients, important information about virus presence in the retina was confirmed [8] . Experimental coronavirus retinopathy (ECOR) occurs after intravitreal inoculation of murine coronavirus (M-CoV, JHM strain) in BALB/c and CD-1 mice. In BALB/c mice, JHM strain induces a biphasic retinal disease characterized by retinal vasculitis observed one to seven days after inoculation (early phase) followed by retinal degeneration in the absence of inflammation (second phase) [9] . The virus can be observed intracellularly within vacuoles and extracellularly at the plasma membrane. [10] The reduction in the interphotoreceptor retinoid-binding protein (IRBP) is a proposed mechanism of retinal damage observed in ECOR models. IRBP is synthesized by retinal photoreceptor cells and acts as an important transport of retinoids between photoreceptors and RPE. The coronavirus could interfere with normal synthesis and/or secretion of IRBP through the rough endoplasmic reticulum and Golgi complex of the photoreceptor cell. Thus, the resultant retinoid excess in the photoreceptor can be toxic [11] . Further investigations found a correlation between higher levels of Interferon-ϒ (IFN-ϒ ) and retinal damage in BALB/c mice after inoculation of JHM strain in the vitreous cavity [12] . There is uncertainty if retinal changes (micro hemorrhages, cotton wool spots) or changes on OCT (hyper reflective dots at the level of inner plexiform or ganglion cell layers) appear days or weeks after the onset of COVID-19 and its relation to the severity of the disease or symptoms [4, 6, 7] . To the best of our knowledge, this is the first case of APMPPE in a convalescent COVID-19 patient. Understanding of the physiopathology is still needed15. naming-the-coron avirus-disea se-(covid-2019)-and-the-virus-that-causes-it Natural history of COVID-19 and current knowledge on treatment therapeutic options Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province China Retinal findings in patients with COVID-19: results from the SERPICO-19 study Endothelial cell infection and endotheliitis in COVID-19 Retinal findings in patients with COVID-19 Vitritis and outer retinal abnormalities in a patient with COVID-19 Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients Murine coronavirus induces an acute and long-lasting disease of the retina Coronavirus (JHM) replication within the retina: analysis of cell tropism in mouse retinal cell cultures Redistribution and reduction of interphotoreceptor retinoid-binding protein during ocular coronavirus infection The critical role of IFN-gamma in experimental coronavirus retinopathy Posterior uveitis of unknown causewhite spot syndromes Spectral domain optical coherence tomography classification of acute posterior multifocal placoid pigment epitheliopathy Inflammatory diseases of the retina and choroid Longterm multimodal imaging in acute posterior multifocal placoid pigment epitheliopathy and association with coxsackievirus exposure Ocular pathology and occasionally detectable intraocular SARS-CoV-2 RNA in five fatal COVID-19 cases Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations